Here's some things to keep in mind...generally doctors should resort to biopsy only after eliminating other possible contributing factors. Know that the positive predictive value following an elevated PSA is low, typically reported to be less than 30%. For those who do advance to prostate biopsy, approximately 30% experience some type of mild to severe symptom from the biopsy process, including pain, fever, bleeding, infection or problems urinating, and about
4% of cases require hospitalization within 30 days.
Here's a bottom-line rule-of-thumb: the harder one looks for PC, the more likely one is to find it.
I'm lukewarm on the PHI test. This test is supposed to detect aggressive prostate cancer with a better specificity than total PSA and percent free PSA in a biopsy-naïve population, and should therefore be a useful tool to decrease unnecessary invasive prostate biopsies. BUT, PHI fails to accurately identify nearly 60% of all patients who (arguably) may not need a biopsy, and on the flipside fails to accurately identify all patients with potentially aggressive disease (i.e., Gleason 4 + 3 = 7 or higher). Arguably, still better than PSA...
Post Edited (JackH) : 3/7/2017 12:49:08 PM (GMT-7)